These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12937870)

  • 1. Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers.
    Otani M; Fukuda T; Naohara M; Maune H; Senda C; Yamamoto I; Azuma J
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):395-9. PubMed ID: 12937870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes.
    Senda C; Yamaura Y; Kobayashi K; Fujii H; Minami H; Sasaki Y; Igarashi T; Chiba K
    Br J Clin Pharmacol; 2001 Jul; 52(1):100-3. PubMed ID: 11453897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
    Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J
    Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects.
    Paczkowski D; Sadowski Z; Filipek M; Koliński P
    Pol J Pharmacol Pharm; 1990; 42(4):365-75. PubMed ID: 2097598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
    Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study.
    Nieminen T; Uusitalo H; Mäenpää J; Turjanmaa V; Rane A; Lundgren S; Ropo A; Rontu R; Lehtimäki T; Kähönen M
    Eur J Clin Pharmacol; 2005 Dec; 61(11):811-9. PubMed ID: 16315032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine.
    Labbé L; Abolfathi Z; Robitaille NM; St-Maurice F; Gilbert M; Turgeon J
    Ther Drug Monit; 1999 Apr; 21(2):191-9. PubMed ID: 10217339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of mexiletine clearance in a Japanese population.
    Ueno K; Tamamura A; Matsumoto K; Komamura K; Kamakura S; Miyatake K; Shibakawa M
    Ann Pharmacother; 2002 Feb; 36(2):241-5. PubMed ID: 11847941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
    Abolfathi Z; Fiset C; Gilbert M; Moerike K; Bélanger PM; Turgeon J
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers.
    Borobia AM; Novalbos J; Guerra-López P; López-Rodríguez R; Tabares B; Rodríguez V; Abad-Santos F; Carcas AJ
    Pharmacol Res; 2009 Jun; 59(6):393-8. PubMed ID: 19429471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
    Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
    J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes.
    Huang J; Chuang SK; Cheng CL; Lai ML
    Clin Pharmacol Ther; 1999 Apr; 65(4):402-7. PubMed ID: 10223777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects.
    Chen B; Cai WM
    Acta Pharmacol Sin; 2003 Dec; 24(12):1277-80. PubMed ID: 14653957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
    Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
    Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men.
    Kusumoto M; Ueno K; Oda A; Takeda K; Mashimo K; Takaya K; Fujimura Y; Nishihori T; Tanaka K
    Clin Pharmacol Ther; 2001 Mar; 69(3):104-7. PubMed ID: 11240973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of experimental diabetes and insulin treatment on the enantioselective pharmacokinetics of mexiletine and its metabolites.
    Pardo Campos Godoy AL; Martinez EZ; Marques MP; de Carvalho Leone A; Barbosa Coelho E; Lucia Lanchote V
    Can J Physiol Pharmacol; 2014 Mar; 92(3):263-6. PubMed ID: 24593792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.
    Giessmann T; Modess C; Hecker U; Zschiesche M; Dazert P; Kunert-Keil C; Warzok R; Engel G; Weitschies W; Cascorbi I; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2004 Mar; 75(3):213-22. PubMed ID: 15001973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects.
    Lim KS; Cho JY; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Shin SG; Yu KS
    Br J Clin Pharmacol; 2008 Nov; 66(5):660-6. PubMed ID: 18754843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype.
    Molden E; Johansen PW; Bøe GH; Bergan S; Christensen H; Rugstad HE; Rootwelt H; Reubsaet L; Lehne G
    Clin Pharmacol Ther; 2002 Sep; 72(3):333-42. PubMed ID: 12235455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.